Zhonghua nan ke xue = National journal of andrology · 2019
[Effect of Yishen Zhuangyang Cream on penile hemodynamics in ED patients].
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Cun-Chao
Аннотация
OBJECTIVE: To observe the effect of Yishen Zhuangyang Cream (YZC) on the hemodynamic parameters of the penile cavernous artery in ED patients and explore its pharmacological mechanisms.
METHODS: Ninety-two outpatients with ED were randomly assigned to receive YZC (n = 60) or placebo ( the control group, n = 32), all for 4 weeks. Comparisons were made between the two groups of patients in the IIEF-5 scores, penile erectile hardness (PEH) scores and the hemodynamic parameters of the penile cavernous artery before and after treatment.
RESULTS: The IIEF-5 and PEH scores were both significantly increased in the YZC group after treatment in comparison with the baseline (19.18 ± 3.56 vs 12.63 ± 3.78, P < 0.01; 3.58 ± 0.50 vs 3.21 ± 0.62, P < 0.01), and higher than in the control group after medication (19.18 ± 3.56 vs 13.72 ± 2.85, P = 0.01; 3.58 ± 0.50 vs 3.28 ± 0.58, P < 0.01), but no statistically significances were observed between the two groups after treatment or within each group before and after medication in the peak systolic velocity (PSV), end-diastolic velocity (EDV), or resistance index (RI) of the penile artery (P > 0.05). The rate of therapeutic effectiveness was remarkably higher in the YZC than in the control group (73.33% vs 21.88%, Z = －4.665, P < 0.01).
CONCLUSIONS: YZC can improve the erectile function of ED patients by increasing IIEF-5 and PEH scores but has no significant effect on penile hemodynamics. The pharmacological mechanisms of YZC acting on ED need to be further studied.
METHODS: Ninety-two outpatients with ED were randomly assigned to receive YZC (n = 60) or placebo ( the control group, n = 32), all for 4 weeks. Comparisons were made between the two groups of patients in the IIEF-5 scores, penile erectile hardness (PEH) scores and the hemodynamic parameters of the penile cavernous artery before and after treatment.
RESULTS: The IIEF-5 and PEH scores were both significantly increased in the YZC group after treatment in comparison with the baseline (19.18 ± 3.56 vs 12.63 ± 3.78, P < 0.01; 3.58 ± 0.50 vs 3.21 ± 0.62, P < 0.01), and higher than in the control group after medication (19.18 ± 3.56 vs 13.72 ± 2.85, P = 0.01; 3.58 ± 0.50 vs 3.28 ± 0.58, P < 0.01), but no statistically significances were observed between the two groups after treatment or within each group before and after medication in the peak systolic velocity (PSV), end-diastolic velocity (EDV), or resistance index (RI) of the penile artery (P > 0.05). The rate of therapeutic effectiveness was remarkably higher in the YZC than in the control group (73.33% vs 21.88%, Z = －4.665, P < 0.01).
CONCLUSIONS: YZC can improve the erectile function of ED patients by increasing IIEF-5 and PEH scores but has no significant effect on penile hemodynamics. The pharmacological mechanisms of YZC acting on ED need to be further studied.